Investment
Features
FeesSafety
Academy
More
Pluang+

HQH fund benefits from healthcare sector rebound, offering 12% yield with focus on biotech and diversification.

Market News
18 Sep 2026
Seeking Alpha
View Source
Bullish
HQH fund benefits from healthcare sector rebound, offering 12% yield with focus on biotech and diversification.

The abrdn Healthcare Investors (HQH) fund is gaining from a healthcare sector rebound after lagging the broader market for a decade. It offers a strong 12% forward distribution yield supported by a managed distribution policy. HQH primarily invests in small and mid-cap biotech companies, while also including select large-cap healthcare stocks. Combining HQH with large-cap healthcare funds can provide investors with balanced income and diversification benefits, making it an attractive option in a traditionally non-cyclical sector like healthcare.

The abrdn Healthcare Investors (HQH) fund is the subject, with Pluang data providing market context. For readers following healthcare sector stocks, here is Pluang's snapshot as of Sep 18, 2026 20:41 WIB: Of 92 priced health-sector US stocks, 35 rose and 55 fell. Notable movers include TWST at USD 158.58 (+2.05%), XRAY at USD 9.56 (+1.97%), and GSK at USD 50.07 (-1.94%). Typical hold times range from 28 to 90 days, with varied Pluang order activity percentages.

More News

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy's stock shows 8.26% upside with strong earnings forecast and mixed institutional interest.

Duke Energy Corporation's stock is projected to rise about 8.26% to a price target of $127, down slightly from $133, reflecting confidence despite a recent price dip. The company expects a 4.42% increase in earnings per share to $1.89 and a 3.86% ris...

Analyst Insights
Bullish
2 hours ago
Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals stock plunges 27.6% after pausing clinical trials due to safety concerns.

Xenon Pharmaceuticals halted new patient enrollment in its psychiatry clinical trials for the drug azetukalner after reports of neuropsychiatric side effects. This pause led to a sharp 27.6% drop in its stock price, marking its worst day since 2017. ...

Market News
Bearish
3 hours ago
Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma beats EPS estimates and secures $75M deal with Sobi, boosting cash runway to 2028

Innate Pharma reported an EPS of -$0.24, beating analyst estimates of -$0.29, and revenue of $6.5 million, slightly above expectations. The company secured a strategic partnership with Sobi for its drug lacutamab, receiving a $75 million upfront paym...

Company Fundamentals
Bullish
3 hours ago
Disney hires Karandeep Anand as new CTO to boost technology and AI across the company.

Disney hires Karandeep Anand as new CTO to boost technology and AI across the company.

Disney has appointed Karandeep Anand, former CEO of Character.AI, as its first chief technology officer, a new role reporting directly to CEO Josh D'Amaro. Anand will oversee Disney's enterprise technology, infrastructure, data, AI platforms, product...

Market News
Bullish
4 hours ago
Cardano's official YouTube channel hacked with fake 'double ADA' scam, warns founder Charles Hoskinson.

Cardano's official YouTube channel hacked with fake 'double ADA' scam, warns founder Charles Hoskinson.

Cardano's official YouTube channel was hacked, broadcasting a fake livestream offering to double investors' ADA tokens. The scam used AI-generated videos of founder Charles Hoskinson and phishing links to steal crypto wallets and seed phrases. Cardan...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App